Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinoma research hub

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).

This study is testing a new medicine called Keytruda after surgery and radiation for advanced skin cancer (cutaneous squamous cell carcinoma). We want to see if it stops the cancer from coming back compared to a dummy treatment.